OncoSec医疗

ONCS NASDAQ
2.570
-0.130
-4.81%
盘后: 2.510 -0.06 -2.33% 17:13 05/23 EDT
开盘
2.750
昨收
2.700
最高
2.800
最低
2.460
成交量
47.07万
成交均量(3M)
58.62万
52周最高
19.60
52周最低
2.460
换手率
6.72%
市值
1,799.00万
分时
5日
1月
3月
1年
5年

评论

暂无数据

相关股票

微牛行情栏目提供OncoSec医疗 ONCS股票价格,OncoSec医疗股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.
展开 >

最近浏览

名称
价格
涨跌幅